#	Pagina
attuale pagina	/open-h2020/projects/210898/index.html
-1	/politiche-coesione/soggetto/ASSINDUSTRIA+CONSULTING+SRL/1.3.30/pag-1/index.html

Opendata, web and dolomites

PEVIA SIGNED

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PEVIA project word cloud

Explore the words cloud of the PEVIA project. It provides you a very rough idea of what is the project "PEVIA" about.

severity occurred historic hemorrhagic vector human underscoring infections vesicular immunogenicity preventive strain clinical induce spread east world proportions health 2014 event outbreak readily global 1976 rural prevention discovery shown larger trials candidates caused humans isolated confined attract patients risk central filoviridae endemic spurred family efficacy monovalent models did drugs mostly caring fatality west dangerous microorganisms combined strains magnitude threat animal gained protect stomatitis viruses public fevers protective sporadic people demonstrating regions rapid causing africa took reached infection virus severe safe species antiviral serious primates approved vaccine workers ebov disease ebola pattern highest zaire vaccines outbreaks lasting lethal immune hence safety healthcare treatment

Project "PEVIA" data sheet

The following table provides information about the project.

Coordinator	ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Organization address address: 3 AVENUE VICTORIA city: PARIS postcode: 75000 website: http://www.aphp.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.pevia-ebola.eu
Total cost	17˙731˙397 €
EC max contribution	6˙189˙570 € (35%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2015-08-single-stage
Funding Scheme	IMI2-RIA
Starting year	2017
Duration (year-month-day)	from 2017-06-01 to 2023-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Organization address address: 3 AVENUE VICTORIA city: PARIS postcode: 75000 website: http://www.aphp.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	coordinator	1˙297˙406.00
2	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 website: www.cea.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS 15)	participant	1˙040˙108.00
3	OLIGOVAX OLIGOVAX Organization address address: 102 AVENUE DES CHAMPS-ELYSEES city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	863˙000.00
4	CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE Organization address address: AVENUE OSCAR LAMBRET 2 city: LILLE postcode: 59037 website: http://www.chru-lille.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	participant	603˙125.00
5	UNIVERSITE D'ABOMEY-CALAVI UNIVERSITE D'ABOMEY-CALAVI Organization address address: CAMPUS UNIVERSITAIRES D ABOMEY city: ABOMEY CALAVI postcode: 1 website: www.bj.refer.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BJ (ABOMEY CALAVI)	participant	566˙312.00
6	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Organization address address: RUE MICHEL ANGE 3 city: PARIS postcode: 75794 website: www.cnrs.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	533˙332.00
7	IFAKARA HEALTH INSTITUTE TRUST IFAKARA HEALTH INSTITUTE TRUST Organization address address: KIKO AVENUE OFF OLD BAGAMOYO ROAD PLOT 463 city: DAR ES SALAAM postcode: n.a. website: http://www.ihi.or.tz/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	TZ (DAR ES SALAAM)	participant	502˙000.00
8	ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO Organization address address: Via Portuense, 292 city: ROMA postcode: 149 website: www.inmi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	273˙650.00
9	ISTITUTO SUPERIORE DI SANITA ISTITUTO SUPERIORE DI SANITA Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 website: http://www.iss.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	246˙887.00
10	BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN Organization address address: BERNHARD NOCHT STRASSE 74 city: HAMBURG postcode: 20359 website: www.bni.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	182˙500.00
11	HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE Organization address address: MARTINISTRASSE 52 city: HAMBURG postcode: 20251 website: www.hpi-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	81˙250.00
12	CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS Organization address address: RUE DU BUGNON 21 city: LAUSANNE postcode: 1011 website: www.chuv.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	0.00
13	EXCELLGENE SA EXCELLGENE SA Organization address address: ROUTE DE L'ILE-AU-BOIS 1A city: MONTHEY postcode: 1870 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (MONTHEY)	participant	0.00
14	VAXEAL RESEARCH VAXEAL RESEARCH Organization address address: 4 RUE PIERRE FONTAINE, PEPINERE GENOPOLE ENTERPRIS city: EVRY postcode: 91058 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (EVRY)	participant	0.00

Map

Project objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEVIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEVIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors